Syntara Limited has released a press release.
PXS Sells Australian Distribution Rights for A$2m
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- PXS Announces First Results in Bone Marrow Cancer Trial
- Quarterly Activity Report
- Appendix 4C - quarterly
- Sale of Russian Distribution Rights
- First Patient Enrolled - Clinical Trial for Cancer Treatment
Later from Syntara
- PXS Drug Decreases Tumour Burden in Liver Cancer Model
- PXS Grants Exclusive Option to Develop High Payload Inhaler
- Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
- PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
- PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara